# Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Source: https://onco.cc/trials/nct06652633/  
OnCo record `nct06652633` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of GLPG CAR T-cell therapy in advanced solid tumours, run by Lakefront Biotherapeutics NV, now recruiting.

## Summary

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies is a phase 3 interventional study registered as NCT06652633 by Lakefront Biotherapeutics NV, with 546 participants planned, started 2024-09-09 and due to reach its primary completion in 2039-07. Interventions recorded: GLPG CAR T-cell therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06652633
- Phase: 3
- Setting: A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies
- Sponsor: Lakefront Biotherapeutics NV
- Enrolled: 546

## Sources

- ClinicalTrials.gov NCT06652633: https://clinicaltrials.gov/study/NCT06652633

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06652633.json